Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic

Trials

Clémentine Schilte¹  Nathalie Jolly¹  Elisabeth Botelho-Nevers²  Amandine Gagneux-Brunon²  Xavier Duval³  Bruno Hoen⁴  Arnauld Garcin⁵  Laura Schaeffer⁶  Muriel Vray⁶ 

[1] Center for Translational Science, Institut Pasteur, Paris, France;Department of Infectious diseases, University Hospital of Saint-Etienne, Saint-Etienne, 42055, France;CIC-1408 Vaccinology, INSERM, University Hospital of Saint-Etienne, Saint-Etienne, 42055, France;Inserm CIC-1425, AP-HP, Hôpital Universitaire Bichat; Inserm UMR-1137 IAME; Université Paris Diderot, UFR de Médecine-Bichat, Paris, France;Institut Pasteur, Paris, France;Unité de Recherche Clinique, Innovation et Pharmacologie, University Hospital of Saint-Etienne, Saint-Etienne, 42055, France;Unité d’Epidémiologie des Maladies Emergentes, Institut Pasteur, INSERM, Paris, France;

关键词: Pre-exposure chemoprophylaxis trial;    SARS-CoV-2 infection;    Healthcare workers;    Acceptability;    Hydroxychloroquine;   

DOI  :  10.1186/s13063-021-05329-y

来源: Springer

【 授权许可】

CC BY